EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Evaluating treatment response to mepolizumab in patients with severe CRSwNP

C Hopkins, J K Han, V J Lund, C Bachert, W J Fokkens, Z Diamant, J Mullol, A R Sousa, S G Smith, S Yang, B Mayer, S W Yancey und 2 weitere

Rhinology Journal · 01.01.2023 · 0-0

DOI: 10.4193/rhin22.200 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Rhinology Journal, online erschienen am 01.01.2023. Verfasst von C Hopkins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of ENT, Guy's Hospital and St Thomas' Hospital, King's College London, UK. Hauptthemen laut MEDLINE: Nasal Obstruction, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP).

Methods

SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS).

Results

Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across ≥ 3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories).

Conclusions

Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal ObstructionNasal PolypsRhinitisHumansQuality of LifeAntibodies, Monoclonal, HumanizedChronic DiseaseAdrenal Cortex Hormones

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of ENT, Guy's Hospital and St Thomas' Hospital, King's College London, UK.
  • Department of Otolaryngology Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
  • Royal National Throat, Nose and Ear Hospital, UCLH NHS Trust, London, UK.
  • Upper Airways Research Laboratory, Faculty of Medicine, Ghent University, Ghent, Belgium.
  • Department of Otolaryngology, Amsterdam University Medical Center, Location AMC, Amsterdam, Netherlands.
  • Department of Microbiology Immunology and Transplantation, KU Leuven, Catholic University of Leuven, Belgium; Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital…

Zitieren

APA

Hopkins, C., Han, J. K., Lund, V. J., Bachert, C., Fokkens, W. J., Diamant, Z., Mullol, J., Sousa, A. R., Smith, S. G., Yang, S., Mayer, B., Yancey, S. W., Chan, R. H., & Lee, S. E. (2023). Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin22.200

Vancouver

Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology Journal. 2023;0(0):0-0. doi:10.4193/rhin22.200

BibTeX
@article{Hopkins2023,
  author = {Hopkins, C and Han, J K and Lund, V J and Bachert, C and Fokkens, W J and Diamant, Z and Mullol, J and Sousa, A R and Smith, S G and Yang, S and Mayer, B and Yancey, S W and Chan, R H and Lee, S E},
  title = {Evaluating treatment response to mepolizumab in patients with severe CRSwNP},
  journal = {Rhinology Journal},
  year = {2023},
  volume = {0},
  number = {0},
  pages = {0--0},
  doi = {10.4193/rhin22.200}
}
Kostenlos starten →